Oragenics financials
$0.4800+1.78%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $7.5K |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $7.5K |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | 100.0% |
| Operating income | -$2.6M | -$2.3M | -$2.5M | -$3.1M | -$1.7M | -$2.0M | -$3.4M | -$2.4M | -$2.3M | -$2.5M | -$12.8M | -$2.1M |
| Net income | -$2.5M | -$2.2M | -$2.3M | -$3.1M | -$2.3M | -$2.2M | -$3.3M | -$2.5M | -$2.3M | -$2.5M | -$12.7M | -$2.0M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | −26960.7% |
| Diluted EPS | $-0.57 | $-0.51 | $-0.40 | $-1.96 | $-3.10 | $-3.65 | $-4.44 | $-11.32 | $-15.27 | $-21.00 | $-147.47 | $-25.50 |
| EBITDA | -$2.6M | -$2.3M | -$2.5M | -$3.1M | -$1.7M | -$2.0M | -$3.4M | -$2.4M | -$2.3M | -$2.5M | -$12.8M | -$2.1M |
| Operating cash flow | -$2.2M | -$2.2M | -$2.8M | -$3.0M | -$1.3M | -$2.1M | -$2.0M | -$2.0M | -$1.5M | -$3.1M | -$1.1M | -$1.5M |
| Free cash flow | -$2.2M | -$2.2M | -$2.8M | -$3.0M | -$1.3M | -$2.1M | -$2.0M | -$2.0M | -$1.5M | -$3.1M | -$1.1M | -$1.5M |
| Diluted shares | 4.4M | 4.3M | 5.7M | 1.6M | 0.7M | 0.6M | 0.8M | 0.2M | 0.2M | 0.1M | 0.1M | 0.1M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $3.9M | $6.1M | $4.4M | $11.4M | $2.0M | $3.4M |
| Short-term investments | $0.00 | $0.00 | $4.0M | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $56.1K | $227.3K | $394.8K | $3.0M | $2.6M |
| Total assets | $5.5M | $7.5M | $10.1M | $12.7M | $2.1M | $3.9M |
| Total liabilities | $1.8M | $1.3M | $1.8M | $2.9M | $4.3M | $3.7M |
| Shareholders' equity | $3.7M | $6.2M | $8.3M | $9.8M | -$2.1M | $137.7K |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology